Lynparza 100mg Tablet

About

Lynparza 100mg Tablet, containing Olaparib, is an oral poly(ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of various cancers. It works by exploiting inherent deficiencies in DNA repair pathways, particularly homologous recombination repair (HRR) deficiencies, which are frequently observed in cancers with germline or somatic BRCA1/2 mutations. By inhibiting PARP enzymes, Olaparib prevents cancer cells from effectively repairing single-strand DNA breaks. This leads to an accumulation of irreparable DNA damage, ultimately triggering synthetic lethality and programmed cell death within the malignant cells. This mechanism makes it particularly effective in BRCA-mutated ovarian, breast, prostate, and pancreatic cancers. Lynparza represents a significant advancement in targeted cancer therapy, offering a precision approach to treatment that leverages specific genetic vulnerabilities of tumors to improve patient outcomes and extend survival.

Uses

• Maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
• Adjuvant treatment of germline BRCA-mutated HER2-negative high-risk early breast cancer.
• Treatment of germline or somatic BRCA-mutated metastatic pancreatic adenocarcinoma.
• Treatment of metastatic castration-resistant prostate cancer with HRR gene mutations.

Directions For Use

Take Lynparza 100mg Tablet orally twice daily, with or without food, as prescribed by your oncologist. Swallow tablets whole; do not chew, crush, or split them.

Benefits

• Targets specific DNA repair deficiencies in cancer cells.
• Significantly improves progression-free survival in responsive cancers.
• Effective in BRCA-mutated ovarian, breast, prostate, and pancreatic cancers.
• Offers a targeted therapy option for patients with specific genetic mutations.
• Available as an oral medication for patient convenience.
• Can be used as maintenance therapy to prolong remission.

Side Effects

• Nausea
• Fatigue/Asthenia
• Vomiting
• Anemia
• Diarrhea
• Decreased appetite
• Abdominal pain
• Myelosuppression (neutropenia, thrombocytopenia)
• Dysgeusia (taste disturbance)
• Headache
• Rash
• Musculoskeletal pain

Safety Measures

• Alcohol - Alcohol consumption should be limited or avoided as it may worsen gastrointestinal side effects or interact with the medication.
• Pregnancy - Lynparza is embryofetal toxic and contraindicated during pregnancy. Women of childbearing potential must use effective contraception during treatment and for 6 months after the last dose.
• Breastfeeding - Breastfeeding is not recommended during treatment with Lynparza and for 1 month after the last dose, due to potential harm to the infant.
• Liver - Use with caution in patients with moderate or severe hepatic impairment; dose adjustments may be necessary. Monitor liver function tests regularly.
• Kidney - Dose adjustments are required for patients with moderate or severe renal impairment. Close monitoring of kidney function is essential.
• Lung - Rare cases of pneumonitis, including fatal cases, have been reported. Monitor for new or worsening respiratory symptoms like dyspnea, cough, or fever.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.